Re: What's the deal with Zenith?
in response to
by
posted on
Jun 24, 2023 08:49AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
tada, great post.
You sentence "DM was not clear about the mechanics of the process so really we are all just blowing smoke at this time anyways. God knows we have heard all kinds of dreams in the past that never got to fruition." hit me like a bolt of lightning.
Having been in this for 13 years I'm willing to bet Don doesn't have a clue about the mechanics. He probably needed some hot idea to through into the RVX AGM because he needed to save face in front of whatever shareholders actually got into the RVX AGM. Probably the accountants on his team have a good idea about this concept.
On a serious note, I have a significant number of ZCC shares and I really don't want to see Don destroy that potential. My hope is that somehow in the next year Don will leave both companies or be forced out.
I will give the team credit for thinking outside the box but I have become so cynical at this stage that I say "prove it before I believe it".
GLTA
Toinv